OVARIAN CANCER and US: ME-344

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label ME-344. Show all posts
Showing posts with label ME-344. Show all posts

Wednesday, April 11, 2012

ME-344/NV-128 - Marshall Edwards - Trials Open for Broad-Acting Oncology Candidate - Chemotherapy Advisor



Trials Open for Broad-Acting Oncology Candidate - Chemotherapy Advisor


close
cer Care Costs Seem to Be Worth It
Read More >>
(ChemotherapyAdvisor) – San Diego-based pharmaceutical company Marshall Edwards, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ME-344, the company's lead mitochondrial inhibitor. A Phase 1 clinical trial of intravenous ME-344 in patients with solid refractory tumors is currently being initiated.
Data from a preclinical study of NV-128, the metabolic precursor of ME-344, demonstrated its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells.....